Healthcare (XLV) vs Industrials (XLI)

Healthcare earnings come from drug volumes, hospital utilization, and managed-care premiums, which are largely inelastic to GDP. Industrial earnings come from aerospace orderbooks, freight volumes, mining and construction equipment cycles, and electrical infrastructure capex, all of which compress when growth slows. Historically the XLV/XLI ratio rises in the six to twelve months before US recessions and falls during the two-year recoveries that follow.

The April 2026 ratio of 0.863 sits inside its three-year range. The ratio bottomed near 0.79 in late 2024 (industrials leading on AI infrastructure capex) and peaked near 0.95 in mid-2022 during the recession scare. A move above 0.92 would indicate defensive rotation has arrived; a sustained move below 0.82 would indicate the cyclical phase is extending.

The 62 holdings in XLV concentrate heavily at the top. Eli Lilly at 13.80 percent reflects the GLP-1 obesity-drug franchise (Mounjaro and Zepbound) generating $40-plus billion in revenue and growing 50 percent year over year. Johnson and Johnson at 10.55 percent provides the diversified pharma-plus-medtech anchor after the Kenvue consumer-health spinoff. AbbVie at 6.74 percent reflects the post-Humira portfolio with Skyrizi and Rinvoq carrying volume growth. UnitedHealth at 6.10 percent and Merck at 5.40 percent round out the top five.

The top five represent approximately 42 percent of XLV. That concentration matters because Lilly alone now drives more daily XLV variance than any other single name. When Lilly disappoints on quarterly script trends or pipeline data, XLV falls hard despite the broader sector being stable.

XLI holds 82 stocks across aerospace and defense, machinery, transports, and electrical equipment. Caterpillar at 7.06 percent reflects mining and construction equipment exposure. The two GE successor companies combined sit at 11.13 percent (GE Vernova at 5.70 percent on grid and gas turbine demand, GE Aerospace at 5.43 percent on commercial-engine aftermarket). RTX at 4.55 percent and Boeing at 3.41 percent provide commercial-aerospace and defense leverage.

The top five represent approximately 26 percent of XLI, less concentrated than XLV. The breadth means XLI tracks underlying cyclical conditions more reliably than any single subsector. Aerospace orderbooks alone (Boeing plus Airbus combined backlog above 14,000 aircraft, eight to ten years at current build rates) provide multi-year visibility that smooths XLI earnings even during macro slowdowns.

XLI has benefited from a broad industrial capex cycle that began around 2023 and accelerated through 2025. Three drivers stand out. First, AI data center buildouts: hyperscaler capex from Microsoft, Google, Meta, and Amazon combined exceeded $400 billion in 2025, with grid equipment, cooling systems, and electrical infrastructure flowing to GE Vernova, Eaton, Quanta, and Trane. Second, defense spending: the Iran war that began February 2026 has accelerated US and allied defense procurement, lifting RTX, Lockheed, Northrop, and General Dynamics. Third, reshoring: CHIPS Act fab construction (TSMC Arizona, Intel Ohio, Samsung Texas) and IRA-driven manufacturing has supported industrial-equipment demand.

The combined effect: XLI gained approximately 22 percent in 2024 and another 15 percent in 2025, outpacing XLV by roughly 12 percentage points cumulatively. The late-2024 trough in XLV/XLI near 0.79 captured the peak relative cyclical strength.

Healthcare underperformance has specific structural causes. UnitedHealth lost roughly 30 percent peak-to-trough during 2024-2025 on Medicare Advantage margin compression, the Change Healthcare cyber incident, and DOJ antitrust investigation. The drag pulled XLV by roughly 2 percentage points given the 6 percent UNH weight. CVS, Humana, and Cigna in adjacent managed-care exposure added similar drag.

Drug-pricing politics added pressure. The IRA Medicare drug price negotiations published their second tranche of 15 negotiated drugs in February 2025, with prices effective January 2026. The list included blockbuster names representing roughly $50 billion in annual revenue. Pharma multiples compressed roughly 2 to 3 turns of forward earnings on the ongoing political risk. The Lilly-led GLP-1 strength has masked but not offset these headwinds at the index level.

XLV/XLI tracks macro regime identifiably. In risk-on cyclical recoveries (2009-2010, 2016-2017, 2020-2021, 2023-2024), XLI leads and the ratio falls. In late-cycle and recession-anticipation phases (2007 H2, 2018 H2, 2022 H1), XLV leads and the ratio rises. In the recession itself, both fall but XLV typically falls less, so the ratio rises further. In the recovery phase, XLI snaps back faster.

The regime-diagnostic value comes from the ratio anticipating what survey data confirms later. ISM Manufacturing PMI, durable goods orders, and capex announcements typically follow the XLV/XLI ratio by two to four months. When the ratio breaks above its 200-day moving average from below, ISM PMI typically rolls over within one quarter.

Both sectors have rate exposure but through different channels. XLV is moderately rate-sensitive: pharma dividends compete with Treasury yields, and pharma R and D economics depend on cost of capital. The dividend-yield spread to the 10-year Treasury at 4.20 percent is modest in April 2026 because pharma yields run 1.5 to 3 percent. Healthcare PE multiples expanded modestly during the 2024 Fed easing cycle (100 basis points of cuts September through December 2024) but less than utilities or REITs.

XLI is more cyclically rate-sensitive: industrial capex buyers borrow heavily, and rate cuts directly stimulate equipment-financing demand. Construction equipment, trucking fleets, and aerospace financing all respond to rates within two to four quarters. The 2024 cuts contributed materially to the late-2024 XLI rally that pushed XLV/XLI to its 0.79 low.

The February 2026 Iran war has produced asymmetric effects on the pair. XLI has gained from defense procurement: RTX, Lockheed, Northrop combined are roughly 9 percent of XLI, and these names rose 15 to 25 percent year-to-date 2026 on accelerated US and allied munitions and missile-defense orders. XLV has been roughly flat: defensive sectors typically benefit during geopolitical risk, but the GLP-1 pricing pressure and drug-pricing political risk have offset the safety bid.

Net result: the XLV/XLI ratio has stayed in the 0.84 to 0.88 range through April 2026 rather than rising decisively to a defensive regime. The market is reading the Iran war as an industrial-demand event (defense capex up) rather than a recession-imminent event (defensives outperforming).

Track three things. First, the 200-day moving average of the XLV/XLI ratio. Currently approximately 0.85. Cross above with rising slope is the late-cycle rotation signal. Second, ISM Manufacturing PMI direction. ISM rolling below 50 with XLV/XLI rising confirms the rotation. Third, Lilly individual performance. Because Lilly is 13.80 percent of XLV, idiosyncratic Lilly moves can drive the ratio without genuine sector rotation. Filter for ratio moves that hold even when ex-Lilly XLV moves are flat.

For pair traders, long XLV / short XLI captures defensive positioning with hedged broad market beta. The trade benefits from ISM rolling below 50, defense-spending peak, and AI capex deceleration. Short XLV / long XLI benefits from continued cyclical strength, ongoing AI capex, and drug-pricing political pressure. Position sizing should account for XLV approximately 16 percent annualized volatility versus XLI approximately 19 percent.

XLV/XLI at 0.863 sits roughly in the middle of its three-year range. Healthcare faces the IRA drug-price negotiation deadlines (next 15 drugs effective January 2027), ongoing Lilly-driven concentration risk, and managed-care DOJ overhang. Industrials face the AI capex peak question (whether 2026-2027 sustains the pace), the Iran war duration, and the durable-goods order trajectory through Q2 and Q3 2026.

Forward-looking: if Iran resolves and AI capex sustains, expect ratio to drift toward 0.84-0.85 (cyclical extending). If recession concerns reignite (ISM rolling, layoffs accelerating), expect ratio to push toward 0.88-0.92 (defensive rotation). The Q1 2026 GDP print, April-May ISM trajectory, and Lilly Q1 earnings on April 30 are the immediate catalysts that will determine which regime dominates the next two quarters.